80 related articles for article (PubMed ID: 9541726)
1. Lipid lowering effects of pravastatin in common marmosets.
Miyazaki A; Koga T
Arzneimittelforschung; 1998 Feb; 48(2):154-60. PubMed ID: 9541726
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
[TBL] [Abstract][Full Text] [Related]
3. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
4. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
Ugawa T; Kakuta H; Moritani H; Shikama H
Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
[TBL] [Abstract][Full Text] [Related]
5. Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits.
Harsch M; Gebhardt A; Reymann A; Lang G; Schliack M; Löser R; Braesen JH; Niendorf A
Br J Pharmacol; 1998 May; 124(2):277-82. PubMed ID: 9641543
[TBL] [Abstract][Full Text] [Related]
6. Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient watanabe heritable hyperlipidemic rabbits.
Shiomi M; Shiraishi M; Yata T; Ito T
Arzneimittelforschung; 1994 Oct; 44(10):1154-6. PubMed ID: 7818592
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
Takayama M; Matsubara M; Arakawa E; Takada C; Ina Y; Hasegawa K; Yao K
Vascul Pharmacol; 2007 Apr; 46(4):302-8. PubMed ID: 17197250
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin sodium, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases serum total cholesterol in Japanese White rabbits by two different mechanisms.
Miyazaki A; Koga T
Atherosclerosis; 2002 Jun; 162(2):299-306. PubMed ID: 11996949
[TBL] [Abstract][Full Text] [Related]
9. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the hypolipidemic effects of coconut water and lovastatin in rats fed fat-cholesterol enriched diet.
Sandhya VG; Rajamohan T
Food Chem Toxicol; 2008 Dec; 46(12):3586-92. PubMed ID: 18809454
[TBL] [Abstract][Full Text] [Related]
11. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits.
Shiomi M; Ito T
Metabolism; 1994 May; 43(5):559-64. PubMed ID: 8177044
[TBL] [Abstract][Full Text] [Related]
12. HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits.
Saga A; Okura H; Soeda M; Tani J; Fumimoto Y; Komoda H; Moriyama M; Moriyama H; Yamashita S; Ichinose A; Daimon T; Hayakawa T; Matsuyama A
Biochem Biophys Res Commun; 2011 Aug; 412(1):50-4. PubMed ID: 21806964
[TBL] [Abstract][Full Text] [Related]
13. Effect of fluvastatin sodium on the smooth muscle cells in atherosclerotic plaques. In vivo study using low-density lipoprotein receptor deficient Watanabe heritable hyperlipidemic (WHHL) rabbits.
Shiomi M; Ito T; Tsukada T; Shiraishi M; Yata T
Arzneimittelforschung; 1998 Jun; 48(6):680-5. PubMed ID: 9689427
[TBL] [Abstract][Full Text] [Related]
14. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor.
Ioriya K; Kino K; Horisawa S; Nishimura T; Muraoka M; Noguchi T; Ohashi N
J Cardiovasc Pharmacol; 2006 Feb; 47(2):322-9. PubMed ID: 16495773
[TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
Nishimoto T; Amano Y; Tozawa R; Ishikawa E; Imura Y; Yukimasa H; Sugiyama Y
Br J Pharmacol; 2003 Jul; 139(5):911-8. PubMed ID: 12839864
[TBL] [Abstract][Full Text] [Related]
17. Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins.
Hofnagel O; Luechtenborg B; Eschert H; Weissen-Plenz G; Severs NJ; Robenek H
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):604-10. PubMed ID: 16373606
[TBL] [Abstract][Full Text] [Related]
18. Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.
Kitayama K; Tanimoto T; Koga T; Terasaka N; Fujioka T; Inaba T
Eur J Pharmacol; 2006 Jul; 540(1-3):121-30. PubMed ID: 16730694
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of rutin on lipids, lipoproteins, lipid metabolizing enzymes and glycoproteins in streptozotocin-induced diabetic rats.
Stanely Mainzen Prince P; Kannan NK
J Pharm Pharmacol; 2006 Oct; 58(10):1373-83. PubMed ID: 17034661
[TBL] [Abstract][Full Text] [Related]
20. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
